Biodel (BIOD) Tops Q2 EPS by 5c

Biodel (NASDAQ: BIOD) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).

At March 31, 2015, Biodel had cash and cash equivalents of $17.8 million and 24.6 million shares of common stock outstanding. After giving effect of the recent public offering, Biodel had cash and cash equivalents of $49.8 million and 62.1 million shares of common stock outstanding.

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "This has been an extremely productive quarter for Biodel. With the exciting data from the recent clinical and human factor studies reported in the GEM program over the past two months and the continued progress made in the BIOD-531 program, coupled with our recent public offering, we are positioned to transition Biodel over the next 12 to 18 months to a later stage product development company with a diversified portfolio and significant potential to build shareholder value."

For earnings history and earnings-related data on Biodel (BIOD) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
• Analysts favorite fintech stock Adyen tumbles after revenue miss